Repeated CD4 counts data from AIDS clinical trial.

Source: AIDS Clinical Trial Group 193A Study.

Description:

The data are from a randomized, double-blind, study of AIDS patients with

advanced immune suppression (CD4 counts of less than or equal to 50 cells/mm^3). Patients in AIDS Clinical Trial Group (ACTG) Study 193A were randomized to dual or triple combinations of HIV-1 reverse transcriptase inhibitors. Specifically, patients were randomized to one of four daily regimens containing 600mg of zidovudine: zidovudine alternating monthly with 400mg didanosine; zidovudine plus 2.25mg of zalcitabine; zidovudine plus 400mg of didanosine; or zidovudine plus 400mg of didanosine plus 400mg of nevirapine (triple therapy).

Measurements of CD4 counts were scheduled to be collected at baseline and at

8-week intervals during follow-up. However, the CD4 count data are unbalanced

due to mistimed measurements and missing data that resulted from skipped visits and dropout. The number of measurements of CD4 counts during the first 40 weeks of follow-up varied from 1 to 9, with a median of 4.

The response variable is the log transformed CD4 counts, log(CD4 counts + 1),

available on 1309 patients.

The categorical variable Treatment is coded

The variable Week represents time since baseline (in weeks).

Variable List:

id: Subject ID

trt: Treatment (1 = zidovudine alternating monthly with 400mg didanosine, 2 = zidovudine plus 2.25mg of zalcitabine, 3 = zidovudine plus 400mg of didanosine, and 4 = zidovudine plus 400mg of didanosine plus 400mg of nevirapine.)

age: Age (years)

sex: Sex at birth (1=M, 0=F)

week: Week since baseline

logcd4: log(CD4 count + 1).

Data courtesy of Dr. Keith Henry.

Reference: Henry, K., Erice, A., Tierney, C., Balfour, H.H. Jr, Fischl, M.A.,

Kmack, A., Liou, S.H., Kenton, A., Hirsch, M.S., Phair, J., Martinez, A.

and Kahn J.O. for the AIDS Clinical Trial Group 193A Study Team (1998).

A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19, 339-349.